THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.87_2629
Abstract: to investigate the signaling pathways altered upon drug treatment. An orthotoppic PDX model was established from a MCL patient with dual resistance to ibrutinib-venetoclax. Single agent copanlisib at 6 mg/kg/2d, idelalisib at 50 mg/kg/2d, ibrutinib… read more here.
Keywords: volasertib; ibrutinib venetoclax; copanlisib; resistance ... See more keywords
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3383-9
Abstract: PurposeTo determine the pharmacokinetics of radiolabeled copanlisib (BAY 80-6946) in healthy male volunteers and to investigate the disposition and biotransformation of copanlisib.MethodsA single dose of 12 mg copanlisib containing 2.76 MBq [14C]copanlisib was administered as a 1-h… read more here.
Keywords: healthy male; copanlisib; male volunteers; 14c copanlisib ... See more keywords
Inhibitory effect of Idelalisib on selenite-induced cataract in Sprague Dawley rat pups.
Sign Up to like & getrecommendations! Published in 2021 at "Current eye research"
DOI: 10.1080/02713683.2021.1988984
Abstract: PURPOSE The aim of this study was to evaluate the therapeutic effect of Idelalisib, Apelisib and Copanlisib on 8-day-old cataract SD rat pups. MATERIALS AND METHODS The rat model induced by sodium selenate (Na2SeO3) was… read more here.
Keywords: copanlisib; rat pups; idelalisib; group ... See more keywords
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-19-0466
Abstract: The PI3K inhibitor copanlisib has efficacy and manageable safety in patients with indolent lymphoma and solid tumors. Pharmacodynamic effects relative to copanlisib dose and plasma exposure were evaluated. Patients with lymphoma or solid tumors received… read more here.
Keywords: copanlisib; pi3k inhibitor; inhibitor copanlisib; solid tumors ... See more keywords
Abstract LB252: Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcomain vivomodels
Sign Up to like & getrecommendations! Published in 2021 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2021-lb252
Abstract: Background. Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Copanlisib was approved for use by the FDA in the treatment… read more here.
Keywords: copanlisib; phosphoinositide kinase; pan class; pi3k ... See more keywords
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s142264
Abstract: The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment… read more here.
Keywords: lymphoma; copanlisib; treatment; follicular lymphoma ... See more keywords